Markets

10.7% of XBI Holdings Seeing Recent Insider Buys

A look at the weighted underlying holdings of the SPDR S&P Biotech ETF (Symbol: XBI) shows an impressive 10.7% of holdings on a weighted basis have experienced insider buying within the past six months.

Keryx Biopharmaceuticals Inc. (Symbol: KERX), which makes up 1.15% of the SPDR S&P Biotech ETF (Symbol: XBI), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $23,258,777 worth of KERX, making it the #12 largest holding. The table below details the recent insider buying activity observed at KERX:

KERX - last trade: $4.62 - Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
05/06/2015 Michael P. Tarnok Director 10,000 $9.73 $97,300
08/12/2015 John F. Neylan Chief Medical Officer 10,000 $6.20 $62,000
08/21/2015 Scott A. Holmes Chief Financial Officer 5,000 $5.72 $28,590
08/20/2015 Greg Madison President and CEO 9,984 $5.68 $56,759

And Merrimack Pharmaceuticals Inc. (Symbol: MACK), the #24 largest holding among components of the SPDR S&P Biotech ETF (Symbol: XBI), shows 3 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $21,607,997 worth of MACK, which represents approximately 1.07% of the ETF's total assets at last check. The recent insider buying activity observed at MACK is detailed in the table below:

MACK - last trade: $10.01 - Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
05/13/2015 Michael E. Porter Director 8,284 $11.79 $97,668
08/12/2015 John M. Dineen Director 100,000 $10.15 $1,015,000
08/12/2015 Michael E. Porter Director 20,000 $10.16 $203,200
08/12/2015 Vivian S. Lee Director 10,000 $10.05 $100,500
08/14/2015 Michael E. Porter Director 13,000 $10.54 $137,040
08/21/2015 Michael E. Porter Director 5,000 $9.76 $48,800

10 ETFs With Stocks That Insiders Are Buying »

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MACK XBI

Other Topics

ETFs